Adenokarcinom prostate sa mikrocelularnom komponentom i niskom vrednosti prostata specifičnog antigena

  • Saša Vojinov Univerzitet u Novom Sadu, Medicinski fakultetKlinički centar Vojvodina , Klinika ya urologiju
  • Mladen Popov University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
  • Ivan Levakov University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
  • Aleksandra Levakov Fejsa Clinical Center of Vojvodina, Department of Urology,Novi Sad, Serbia
  • Dimitrije Jeremić University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
  • Dragan Grbić Clinical Center of Vojvodina, Department of Urology, Novi Sad, Serbia
DOI: https://doi.org/10.2298/VSP181212029V
Ključne reči: prostata, neoplazme, prostata, specifični antigen, dijagnostičke tehnike i procedure, prostatektomija, lečenje lekovima, prognoza

Sažetak


Uvod. Karcinom prostate je jedan od najčešćih malignih oboljenja kod muškaraca. Najčešći tip je adenocarcinom prostate. Karcinom malih ćelija prostate (KMĆP) obično se javlja u kombinaciji sa adenokarcinom prostate. Prikaz bolesnika. Prikazan je 72-godišnji bolesnik sa simptomima otežanog pražnjenja mokraćne bešike. Inicijalni nivo prostata specifičnog antigena (PSA) bio je 2,87 ng/mL. Uzeto je dvanaest bioptata prostate i u šest je otkriveno maligno tkivo. Analizirano tkivo najviše je odgovaralo “karcinomu malih ćelija”. Scintigrafija skeleta nije otkrila širenje karcinoma u skeletnom sistemu. Kompjuterizovana tomografija (KT) male karlice nije otkrila infiltraciju okolnog tkiva tumorom. Bolesnik je operisan – urađena je radikalna retropubična prostatektomija. Patohistološka analiza pokazala je slabo diferentovani adenokarcinom prostate sa zonama karcinoma malih ćelija [Gleason skor 5 + 5 (10), razred II, pT3bN1, stadijum IV]. Zaključak. Slabo diferentovan adenokarcinom prostate, posebno u kombinaciji sa karcinomom malih ćelija, jeste agresivan maligni tumor koji je u većini slučajeva povezan sa opsežnim širenjem bolesti u trenutku postavljanja dijagnoze i ima lošu prognozu. KMĆP izuzetno su retki tumori neuroendokrinog porekla. Bolesnici sa mešovitim karcinomom prostate imaju bolju prognozu i veću stopu preživljavanja. Trenutno ne postoje vodiči zasnovani na dokazima za lečenje ove vrste karcinoma prostate.

Reference

Nwaneri AC, McBeth L, Hinds TD Jr. Prostate Cancer in Afri-can American Men: The Effect of Androgens and microRNAs on Epidermal Growth Factor Signaling. Horm Cancer 2016; 7(5–6): 296–304.

Têtu B, Ro JY, Ayala AG, Johnson DE, Logothetis CJ, Ordonez NG. Small cell carcinoma of the prostate. Part I. A clinico-pathologic study of 20 cases. Cancer 1987; 59(10): 1803–9.

Aparicio A, Tzelepi V. Neuroendocrine (small-cell) carcinomas: why they teach us essential lessons about prostate cancer. On-cology (Williston Park) 2014; 28(10): 831–8.

Palmgren JS, Karavadia SS, Wakefield MR. Unusual and un-derappreciated: small cell carcinoma of the prostate. Semin Oncol 2007; 34(1): 22–9.

Abbas F, Civantos F, Benedetto P, Soloway MS. Small cell carci-noma of the bladder and prostate. Urology 1995; 46(5): 617–30.

Humphrey PA. Histological variants of prostatic carcinoma and their significance. Histopathology 2012; 60(1): 59–74.

Farach A, Ding Y, Lee M, Creighton C, Delk NA, Ittmann M, et al. Neuronal Trans-Differentiation in Prostate Cancer Cells. Prostate 2016; 76(14): 1312–25.

Klimstra DS, Beltran H, Lilenbaum R, Bergsland E. The spec-trum of neuroendocrine tumors: histologic classification, unique features and areas of overlap. Am Soc Clin Oncol Educ Book 2015: 92–103.

Deorah S, Rao MB, Raman R, Gaitonde K, Donovan JF. Survival of patients with small cell carcinoma of the prostate during 1973–2003: a population-based study. BJU Int 2012; 109(6): 824–30.

Wenk RE, Bhagavan BS, Levy R, Miller D, Weisburger W. Ec-topic ACTH, prostatic oat cell carcinoma, and marked hyper-natremia. Cancer 1977; 40(2): 773–8.

Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A et al. Results of a phase II study with doxorubicin, etopo-side, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002; 20(14): 3072–80.

Amato RJ, Logothetis CJ, Hallinan R, Ro JY, Sella A, Dexeus FH. Chemotherapy for small cell carcinoma of prostatic origin. J Urol 1992; 147(3 Pt 2): 935–7.

Lynch SP, Shen Y, Kamat A, Grossman HB, Shah JB, Millikan RE, et al. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term out-comes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol 2013; 64(2): 307–13.

Beltran H, Tagawa ST, Park K, MacDonald T, Milowsky MI, Mos-quera JM, et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol 2012; 30(36): e386–9.

Mosquera JM, Beltran H, Park K, MacDonald TY, Robinson BD, Tagawa ST, et al. Concurrent AURKA and MYCN gene am-plifications are harbingers of lethal treatment-related neuro-endocrine prostate cancer. Neoplasia 2013; 15(1): 1–10.

Objavljeno
2021/02/11
Broj časopisa
Vol. 77 Br. 10 (2020): Vojnosanit pregl
Rubrika
Prikaz bolesnika